TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis

Oncogene

Volumn 35, Issue 6, 2016, Pages 748-760

  Pang, M F ^a,b   Georgoudaki, A M ^a   Lambut, L ^a   Johansson, J ^a   Tabor, V ^a   Hagikura, K ^a,c   Jin, Y ^a   Jansson, M ^d   Alexander, J S ^e   Nelson, C M ^b   Jakobsson, L ^a   Betsholtz, C ^a   Sund, M ^d   Karlsson, M C I ^a   Fuxe, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Princeton University   (United States)

^c NIHON UNIVERSITY   (Japan)

^d UMEÅ UNIVERSITY   (Sweden)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHEMOKINE RECEPTOR CCR7; MITOGEN ACTIVATED PROTEIN KINASE P38; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR JUNB; TRANSFORMING GROWTH FACTOR BETA1; CCL21 PROTEIN, HUMAN; CCR7 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TGFB1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CELL MIGRATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPH VESSEL; LYMPHATIC SYSTEM; MEDIATOR; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR EMBOLISM;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL21; CHEMOTAXIS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASTIC CELLS, CIRCULATING; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RECEPTORS, CCR7; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84958039742     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.133     Document Type: Article

References (47)

1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52: 1551-1557.
2. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364: 412-421.
3. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-1778.
4. Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, Butz S et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med 2007; 204: 2349-2362.
5. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003; 5: 31-36.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
8. Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1: 303-314.
9. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
10. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-176.
11. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
12. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
13. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143: 381-389.
14. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol 2008; 29: 613-616.
15. Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012; 22: 455-461.
16. Johansson J, Tabor V, Wikell A, Jalkanen S, Fuxe J. TGF-beta1-Induced epithelialmesenchymal transition promotes monocyte/macrophage properties in breast cancer cells. Front Oncol 2015; 5: 3.
17. Fuxe J, Vincent T, Garcia de Herreros A. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle 2010; 9: 2363-2374.
18. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 2009; 11: 943-950.
19. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009; 11: 1287-1296.
20. Lappin MB, Weiss JM, Delattre V, Mai B, Dittmar H, Maier C et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98: 181-188.
21. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93: 1638-1643.
22. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10: 2462-2477.
23. Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perez-del-Pulgar S et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 2003; 66: 102-112.
24. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001; 194: 797-808.
25. Cote SC, Pasvanis S, Bounou S, Dumais N. CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP (2)/EP(4) receptors activation. Mol Immunol 2009; 46: 2682-2693.
26. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21: 4104-4113.
27. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C et al. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J Biol Chem 2012; 287: 3581-3590.
28. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005; 95: 918-931.
29. Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Soderberg O, Koinuma D et al. Specific interactions between Smad proteins and AP-1 components determine TGFbeta-induced breast cancer cell invasion. Oncogene 2013; 32: 3606-3615.
30. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005; 5: 617-628.
31. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
32. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
33. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012; 22: 396-403.
34. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006; 94: 1643-1649.
35. Cunningham HD, Shannon LA, Calloway PA, Fassold BC, Dunwiddie I, Vielhauer G et al. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice. Transl Oncol 2010; 3: 354-361.
36. Issa A, Le TX, Shoushtari AN, Shields JD, Swartz MA. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 2009; 69: 349-357.
37. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
38. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007; 11: 526-538.
39. Biswas S, Sengupta S, Roy Chowdhury S, Jana S, Mandal G, Mandal PK et al. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat 2014; 143: 265-276.
40. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003; 3: 921-930.
41. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
42. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006; 102: 453-461.
43. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004; 100: 499-506.
44. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-196.
45. Chladkova B, Kamanova J, Palova-Jelinkova L, Cinova J, Sebo P, Tuckova L. Gliadin fragments promote migration of dendritic cells. J Cell Mol Med 2011; 15: 938-948.
46. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-2036.
47. Choi B, Lim HC, Lee ES, Anower AK, Sohn S. CCL21 attenuates HSV-induced inflammation through up-regulation of CD8+ memory cells. Immunobiology 2013; 218: 579-590.